Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: A 5-Year Follow-Up

Journal of Addictive Diseases

Volumn 32, Issue 3, 2013, Pages 244-251

  Fareed, Ayman ^a,b   Patil, Dustin ^c   Scheinberg, Kelly ^a,b   Blackinton Gale, Robin ^d   Vayalapalli, Sreedevi ^b   Casarella, Jennifer ^a,b   Drexler, Karen ^a,b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

buprenorphine; maintenance; methadone; prolongation; QTc interval

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MORTALITY; QT PROLONGATION;

ADULT; AGED; BUPRENORPHINE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; EPIDEMIOLOGIC METHODS; FEMALE; HEART FAILURE; HUMANS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); TIME FACTORS;

EID: 84885359975     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550887.2013.824333     Document Type: Article

References (27)

1. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. JAMA 1965; 193:80-4.
2. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 1966; 66:2011-7.
3. Latowsky M. Methadone death, dosage, and torsade de pointes: risk-benefit policy implications. J Psychoactive Drugs 2006; 38:513-9.
4. Cruciani RA. Methadone: to ECG or not to ECG . . . That is still the question. J Pain Symptom Manage 2008; 36:545-52.
5. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167:2469-75.
6. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105:499-506.
7. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on longterm methadonemaintenance therapy. Eur Addict Res 2005; 11:44-9.
8. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007; 93:1051-5.
9. Cruciani RA, Sekine R, Homel P, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005; 29:385-91.
10. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. AmJ Cardiol 2005; 95:915-8.
11. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc Interval Screening in Methadone Treatment. Ann Intern Med 2009; 150:387-95.
12. Martin JA, Campbell A, Killip T, et al. QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. J Addict Dis 2011; 30:283-306.
13. Fareed A, Vayalapalli S, Byrd Sellers J, et al. Onsite QTc interval screening for patients in methadone maintenance treatment. J Addict Dis 2010; 29:15-22.
14. Fareed A, Vayalapalli S, Scheinberg K, Gale R, Casarella J, Drexler K. QTc interval prolongation for patients in methadone maintenance treatment: A five years follow up study. Am J Drug Alcohol Abuse 2013; 39:235-40.
15. Katchman AN, McGoary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K+ currents. J Pharmacol Exp Ther 2002; 303:688-94.
16. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: A mortality assessment study. Addiction 2009; 104: 993-9.
17. Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsades de pointes. Pharmacotherapy 2005; 25:611-4.
18. Stallvik M, Nordstrand B, Kristensen , Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine-relation to doses and serum concentrations. Drug Alcohol Depend 2013; 129(1-2):88-93.
19. Krantz M, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-highdose methadone. Ann Intern Med 2002; 137:501-4.
20. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy 2003; 23: 802-5.
21. Florian J, Garnett CE, Nallani SC, Rappaport BA, Throckmorton DC. A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clin Pharmacol Ther 2012; 91:666-72.
22. Huh B, Park CH. Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients. Korean J Anesthesiol 2010; 58:338-43.
23. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services and outcome. New York: Springer-Verlag, 1991.
24. Broers B, Morabia A, Hirschel B. A cohort study of drug users compliance with zidovudine treatment. Arch Intern Med 1994; 154:1121-7.
25. Brugal MT, Domingo-Salvany A, Puig R, et al. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005; 100:981-9.
26. Smyth B, Hoffman V, Fan J, et al. Years of potential life lost among heroin addicts 33 years after treatment. Prev Med 2007; 44:369-74.
27. Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation Drug Alcohol Rev 2011; 30:388-96.